Ozempic and Pregnancy: What to Know Before and During

Over the past three years, GLP-1 receptor agonists have become among the most widely prescribed medications in the United States. Semaglutide — sold as Ozempic for type 2 diabetes and Wegovy for chronic weight management — and tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) are now taken by millions of women of reproductive age. That overlap between the patient population for these medications and the population planning a pregnancy means that questions about Ozempic and pregnancy are arriving in OB-GYN offices and midwifery practices daily.

This guide covers what is currently known — and what remains uncertain — about GLP-1 medications in the preconception and pregnancy period, and how to structure the conversation with your provider so that your care plan is individualized to your situation.

Why Are GLP-1 Medications Paused Before Conception?

GLP-1 receptor agonists work by mimicking the action of glucagon-like peptide-1, a gut hormone that stimulates insulin release, suppresses glucagon, slows gastric emptying, and signals satiety to the brain. These effects are valuable for blood sugar control and weight management — and the nausea they cause (a well-recognized side effect) reflects how significantly they alter the gut's signaling environment. A 2024 PMC study found that the nausea from GLP-1 medications responded to acupressure wristbands, the same mechanism studied for pregnancy morning sickness — a useful indicator that the mechanism is biologically real and not trivial.

The reason these medications are paused before pregnancy is straightforward: the FDA prescribing information for both Ozempic and Wegovy states that they should be discontinued at least two months before a planned pregnancy. The basis for this recommendation is:

• Animal reproduction studies: High-dose semaglutide caused embryo-fetal toxicity and skeletal abnormalities in animal models. These findings do not automatically translate to humans at therapeutic doses, but they are sufficient to warrant precaution in the absence of reassuring human data.
• Insufficient human evidence: Pregnancy registries for semaglutide and tirzepatide are still accumulating data. Sample sizes are too small to definitively characterize human teratogenic risk. The absence of confirmed harm is not the same as confirmed safety.
• Caloric restriction effects: GLP-1 agonists reduce appetite and caloric intake substantially. Significant caloric restriction during early organogenesis — when fetal organ systems are forming at extraordinary speed between weeks 3 and 10 — may limit nutrient delivery at a critical window. This is a theoretical but clinically relevant concern.
• GLP-1 receptors in fetal and placental tissue: Fetal and placental tissue express GLP-1 receptors, raising the possibility that exogenous GLP-1 agonism could affect placental nutrient transport or fetal development in ways that are not yet characterized.

The practical consequence: if you are taking semaglutide or tirzepatide and planning a pregnancy, the medication review conversation with your provider should happen before you start trying — not after a positive test.

What Does the Preconception Medication Review Look Like?

ACOG Committee Opinion No. 762, the guiding document for preconception counseling, explicitly calls for a thorough review of all prescription and nonprescription medications before conception. The goals of that review are to identify known teratogens, weigh the risk-benefit balance for continuing essential medications, and adjust dosages where pregnancy changes pharmacokinetics.

For a woman on a GLP-1 receptor agonist, the preconception medication review typically includes:

• Reason for the medication: Type 2 diabetes, obesity without diabetes, PCOS-related metabolic dysfunction, or another indication each carries a different clinical picture. The underlying condition — not just the drug — is part of the risk assessment.
• Washout planning: The two-to-three-month washout window needs to be built into the conception timeline. Semaglutide has an elimination half-life of approximately one week, so five half-lives (about five weeks) clears the majority of the drug. The two-month minimum adds a safety margin for complete clearance and metabolic restabilization.
• Alternative management: For type 2 diabetes, insulin is the pregnancy standard; for PCOS-related insulin resistance, metformin is sometimes continued under physician guidance. For weight management without diabetes, the focus shifts to nutritional quality and appropriate gestational weight gain targets.
• Contraception during the washout: If pregnancy is not yet intended, reliable contraception during the washout period is important — particularly because GLP-1 medications can restore ovulatory regularity in women with PCOS or obesity-related anovulation, making unintended pregnancy more likely than it was before treatment.
• Nutrient status baseline: ACOG also recommends ensuring folic acid supplementation is in place at least one month before conception — ideally three months. Periconceptional folic acid at 400–800 mcg daily reduces neural tube defect risk by 75–80%; the neural tube closes by day 28 of embryonic life, before most women know they are pregnant.

How GLP-1 Medications Interact With Fertility

One nuance that often surprises patients: for some women, GLP-1 medications may actually improve fertility before they are stopped. Women with PCOS or obesity-related ovulatory dysfunction frequently have irregular or absent cycles driven by insulin resistance. GLP-1 agonists improve insulin sensitivity and support weight loss, both of which can restore more regular ovulation. For a woman who was anovulatory before starting semaglutide, the medication may have already created a more fertile hormonal environment — and stopping it for the washout period may not reverse those gains if the weight loss has been maintained.

The practical implication: women who assume they have low fertility due to irregular cycles may be surprised by how quickly conception becomes possible once the washout is complete. This is another reason why the preconception conversation — including contraception planning during the washout if pregnancy is not yet desired — is so important to have proactively.

According to ACOG's prepregnancy care guidance, the preconception visit is the ideal setting to address chronic condition management, medication safety, vaccination status, and nutrient sufficiency — all of which are relevant for a woman transitioning off a GLP-1 medication and preparing to conceive.

Managing Nausea: The Overlap Between GLP-1 Side Effects and Morning Sickness

One often-overlooked aspect of the Ozempic-and-pregnancy conversation is the nausea overlap. GLP-1 medications cause nausea in a meaningful proportion of users — it is the most common reason for dose-adjustment or discontinuation. First-trimester morning sickness affects roughly 70–80% of pregnant women, typically beginning between weeks 4 and 9. Women who have experienced GLP-1 nausea and then encounter first-trimester nausea may find the combined physiological territory particularly difficult if medications are not timed carefully.

Stopping the GLP-1 medication before conception eliminates one source of nausea. For first-trimester morning sickness that persists, the ACOG- and AAFP-endorsed first-line approach is pyridoxine (vitamin B6) at 10–25 mg every 8 hours combined with doxylamine 12.5 mg — available over the counter and effective in reducing symptoms in up to 70% of women who use them correctly. Ginger at 250 mg four times daily is a well-supported non-pharmaceutical option. Sea-Band acupressure wristbands are a low-risk adjunct; the 2024 PMC study on GLP-1 nausea and acupressure found a biologically plausible mechanism linking these interventions, though data specific to pregnancy morning sickness remain mixed.

What to Discuss With Your Provider Before Stopping Ozempic

To make the most of your preconception appointment, come prepared with answers to these questions — and expect your provider to ask them:

• Why were you prescribed the medication? Diabetes management, weight loss, PCOS, or another reason each leads to a different transition plan.
• How long have you been on it and at what dose? Higher doses and longer duration may warrant a more gradual taper rather than abrupt discontinuation, particularly for metabolic stability.
• What is your current A1C or fasting glucose if you have diabetes? Poorly controlled blood sugar at conception and in early pregnancy significantly increases the risk of neural tube defects and other structural anomalies — potentially a larger risk than the GLP-1 medication itself.
• What is your menstrual cycle history? If your cycles were irregular before the medication and have regularized on it, your provider needs to anticipate what happens after stopping.
• Are you taking a prenatal vitamin with methylfolate? The NIH and ACOG recommend starting folic acid supplementation at least one month — and ideally three months — before attempting conception.

The preconception appointment is not a formality. It is the single most effective intervention for reducing medication-related and nutritional risk in early pregnancy — the period when most of the critical decisions are already being made at the cellular level, long before a positive test.